AeroRx Therapeutics Inc.: Phase 2 study in COPD, Chronic Obstructive Pulmonary Disease (COPD) (64 participants)
AeroRx Therapeutics Inc.: Phase 2 study in COPD, Chronic Obstructive Pulmonary Disease (COPD) (64 participants). Its enrollment of 64 is below the median of 80 (43rd percentile). Dated 10 days ago, it is in the active follow-up window. Score 80/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 64 · 43th percentile of 8,879 ClinicalTrialStartPulse records · 0.8x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | AeroRx Therapeutics Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients |
| NCT ID | NCT07896252 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic; Lung Diseases, Obstructive |
| Intervention types | drug |
| Target enrollment | 64 |
| Site countries | United Kingdom |
| Posted | 2026-10-26 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-26 |
| enrollment percentile | 43th of 8,879 (median 80, 0.8x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch AeroRx Therapeutics Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock AeroRx Therapeutics + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: AeroRx Therapeutics Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- AeroRx Therapeutics Inc.'s enrollment: 43rd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
80 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for AeroRx Therapeutics Inc.?
AeroRx Therapeutics Inc. registered a Phase 2 study (NCT07896252) in COPD targeting 64 participants, posted 2026-10-26.
How does AeroRx Therapeutics Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 64 is below the median (43th percentile); smaller records often move faster and face less competition. It is fresh: dated 10 days ago, inside the window where early outreach matters most. Its Score of 80/100 puts it among the stronger signals in this feed.
AeroRx Therapeutics Inc. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| AeroRx Therapeutics Inc. | NONUS | 64 | 43rd | 2026-10-26 |
| BeOne Medicines | NONUS | 100 | 60th | 2026-11-03 |
| Nurix Therapeutics, Inc. | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 166 | 73rd | 2026-11-03 |
Related records
- Nurix Therapeutics, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Apogee Therapeutics, Inc.
- Janssen Research & Development, LLC
- BeOne Medicines
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor AeroRx Therapeutics Inc. and peer phase 2 records
Get new ClinicalTrialStartPulse records like AeroRx Therapeutics Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.